Andrew Baum
Stock Analyst at Citigroup
(1.27)
# 1643
Out of 5,329 analysts
48
Total ratings
52.00%
Success rate
14.77%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
MRK Merck & Co | Maintains: Buy | 125 115 | 83.31 | 38.04% | 9 | Feb 5, 2025 | |
PFE Pfizer | Maintains: Neutral | 30 29 | 23.91 | 21.29% | 6 | Jan 28, 2025 | |
BMY Bristol-Myers Squibb | Maintains: Neutral | 60 65 | 49.49 | 31.34% | 9 | Jan 28, 2025 | |
RPRX Royalty Pharma | Maintains: Buy | 60 40 | 32.49 | 23.11% | 2 | Oct 25, 2024 | |
ABBV AbbVie | Maintains: Strong Buy | 170 215 | 193.41 | 11.16% | 11 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 675 895 | 794.79 | 12.61% | 7 | Apr 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 5 10 | 7.95 | 25.79% | 3 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Jul 5, 2017 |